An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib‐based chemotherapy
Internal Medicine Journal · 2026
DOI: 10.1111/imj.70335 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2026. Verfasst von Anthea Gibbons und 9 weiteren Autor:innen. Beteiligte Einrichtung: Princess Alexandra Hospital, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Amyloidosis, Immunoglobulin Light Chains, Pyrazines, Boronic Acids. Die Arbeit nennt 19 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Immunoglobulin light chain (AL) amyloidosis is a rare but devastating monoclonal gammopathy where organ failure develops secondary to tissue deposition of misfolded immunoglobulin light chains.
Aims
We aimed to describe the characteristics and outcomes of a uniformly treated cohort of Australian patients with AL amyloidosis.
Methods
Subjects required a histological diagnosis of AL amyloidosis, symptomatic organ involvement and initial treatment with a bortezomib‐based regimen. Kaplan–Meier survival analysis was performed and the impact of baseline variables on response was assessed using Cox regression testing.
Results
Of 271 patients with AL amyloidosis, median age was 66 years and 53% were male. Seventy‐five per cent of cases were lambda restricted, 79% had cardiac involvement and 64% had renal involvement. Overall haematological response rate was 82% being complete in 31% and very good partial response in 36%. Eight per cent of patients died prior to response assessment. Median overall survival was 74 months with inferior overall survival independently associated with more advanced cardiac disease ( P = 0.022 for cardiac stage IIIA and P < 0.0001 for stage IIIB), age ( P = 0.016) and autonomic neuropathy ( P = 0.003). A 6‐month landmark analysis demonstrated a significant impact of the depth of haematologic response on overall survival.
Conclusions
We provide the first description of a large cohort of Australian patients with AL amyloidosis. Two‐thirds of patients achieve deep haematological responses with bortezomib‐based therapy. We confirm the major impact of the severity of cardiac involvement on survival in AL amyloidosis, with stage IIIB disease portending a particularly poor outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Alexandra Hospital, Brisbane, Queensland, Australia.
- School of Medicine, University of Queensland, Brisbane, Australia.
- Fiona Stanley Hospital, Perth, Western Australia, Australia.
- Curtin Medical School, Perth, Western Australia, Australia.
- Eastern Health, Melbourne, Victoria, Australia.
- Eastern Clinical School, Monash University, Melbourne, Victoria, Australia.
ORCID-Profile: Anthea Gibbons, Hasib Sidiqi, Stephen Ting, Brendan Wisniowski, Nirija Ranjit Anderson, Olga Motorna, Peter Mollee
Zitieren
APA
Gibbons, A., Chakravorty, L., Sidiqi, H., Ting, S., Kwok, F., Wisniowski, B., Ranjit Anderson, N., Korczyk, D., Motorna, O., & Mollee, P. (2026). An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib‐based chemotherapy. Internal Medicine Journal. https://doi.org/10.1111/imj.70335
Vancouver
Gibbons A, Chakravorty L, Sidiqi H, Ting S, Kwok F, Wisniowski B, et al. An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib‐based chemotherapy. Internal Medicine Journal. 2026. doi:10.1111/imj.70335
BibTeX
@article{Gibbons2026,
author = {Gibbons, Anthea and Chakravorty, Lipi and Sidiqi, Hasib and Ting, Stephen and Kwok, Fiona and Wisniowski, Brendan and Ranjit Anderson, Nirija and Korczyk, Dariusz and Motorna, Olga and Mollee, Peter},
title = {An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib‐based chemotherapy},
journal = {Internal Medicine Journal},
year = {2026},
doi = {10.1111/imj.70335}
}
EUVIMED